The online version of this article (doi:10.1007/s13555-014-0060-3) contains supplementary material, which is available to authorized users.
Cradle cap is a very common condition in infants that presents as greasy, scaly patches on the scalp within the first weeks of life. Although usually disappearing by itself, the condition worries parents because of its appearance. When removing the scales, it is crucial to prevent spot bleedings to avoid infections. The investigational medical device LOYON® (Cetiol® CC, dimethicone) solution (G. Pohl-Boskamp GmbH & Co. KG, Hohenlockstedt, Germany) has the potential to meet these needs since it removes scales gently. It was, therefore, the aim of this proof-of-concept study to assess the efficacy and safety of topically applied, non-medicated LOYON® in facilitating the removal of scaling in infants and children with cradle cap without inducing spot bleedings.
This single-center, open, proof-of-concept, pilot study was conducted in 20 male or female infants/children aged 3–36 months with clinically diagnosed cradle cap. The 8-day study period included one to three applications of LOYON®. Clinical assessment of scaling and secondary parameters was performed at baseline and after treatment. Adverse events were recorded. A questionnaire on subjective efficacy and usability was handed out to the parents.
With a maximum of three applications of LOYON® applied to 20 subjects, a reduction in scaling intensity from moderate or severe to very mild or mild was achieved in 80% of the subjects. Treatment success, defined as the reduction of the scaling baseline score by at least two points, was achieved in 50% of subjects. Results of this study do not indicate any safety concern. No spot bleedings were observed. LOYON® was generally well tolerated and overall treatment was rated as “good” by the parents/legal guardians.
This study suggests that LOYON® is well tolerated, safe and effective in facilitating the removal of scaling in infants and children with cradle cap. With its gentle approach and rapid effect, LOYON® thus represents a good alternative to home remedies for treatment of cradle cap.
Smoker AL. On top of cradle cap. J Fam Health Care. 2007;17(4):134–6. PubMed
Steward M. Cradle cap. Community Outlook 1990;18.
Johnson M-LT, Roberts J. Prevalence of dermatological disease among persons 1–74 years of age: United States. Advance data from Vital and Health Statistics National Center for Health Statistics; U S Department of Health, Education, and Welfare 1977;No 4:1–7.
Sachdeva M, Kaur S, Nagpal M, Dewan SP. Cutaneous lesions in new born. Indian J Dermatol Venereol Leprol. 2002;68(6):334–7. PubMed
Janniger CK. Infantile seborrheic dermatitis: an approach to cradle cap. Cutis. 1993;51(4):233–5. PubMed
O’Connor NR, McLaughlin MR, Ham P. Newborn skin: part I. Common rashes. Am Fam Phys. 2008;77(1):47–52.
Arora V, Arora S. Management of infantile seborrheic dermatitis. Am Fam Physician. 2007;75(6):807. PubMed
Fleischer AB Jr. Diagnosis and management of common dermatoses in children: atopic, seborrheic, and contact dermatitis. Clin Pediatr (Phila). 2008;47(4):332–46. CrossRef
Zuniga R, Nguyen T. Skin conditions: common skin rashes in infants. FP Essent. 2013;407:31–41. PubMed
Sheffield RC, Crawford P, Wright ST, King VJ. Clinical inquiries. What’s the best treatment for cradle cap? J Fam Pract. 2007;56(3):232–3. PubMed
Shohat M, Mimouni M, Shuper A, Varsano I. Adrenocortical suppression by topical application of glucocorticosteroids in infants with seborrheic dermatitis. Clin Pediatr (Phila). 1986;25(4):209–12. CrossRef
Williams C. Olive oil for cradle cap? Community Pract. 2010;83(11):14. PubMed
Hill K. Industrial development and application of biobased oleochemicals. Pure Appl Chem. 2007;79(11):1999–2011. CrossRef
- Topical, Non-Medicated LOYON® in Facilitating the Removal of Scaling in Infants and Children with Cradle Cap: a Proof-of-Concept Pilot Study
Ulrich R. Hengge
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II